Recon: Baxter resumes IV solution production at hurricane-impacted facility; Teva hit with €463M antitrust fine over Copaxone practices
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States